12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Jul 9 at 07:05 AMAPVO+0.46%IONS+1.22%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 8 at 04:05 PMAPVO+0.46%BRTX-7.17%
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors | APVO Stock NewsStockTitan·Jun 29 at 11:05 PMAPVO+0.46%
Aptevo Therapeutics posts investor presentation on multispecific immunotherapies for cancer, led by mipletamig in AMLPUBT·Jun 25 at 11:25 AMAPVO+0.46%
Aptevo Therapeutics files Form 3 initial beneficial ownership statement for Niowave IncPUBT·Jun 22 at 10:45 AMAPVO+0.46%
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer | APVO Stock NewsStockTitan·May 27 at 11:05 PMAPVO+0.46%IBB-0.44%
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock NewsStockTitan·May 12 at 11:05 PMAPVO+0.46%SBIO-0.88%
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection | APVO Stock NewsStockTitan·May 5 at 11:05 PMAPVO+0.46%IBBQ-0.55%
Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)Tip Ranks·Mar 27 at 10:25 AMIBB-0.44%APVO+0.46%
Aptevo Provides State of the Business Report and 2025 Financial Results | APVO Stock NewsStockTitan·Mar 25 at 11:05 PMIBBQ-0.55%BBH-0.23%
Aptevo to Participate in March 2026 Conferences | APVO Stock NewsStockTitan·Mar 18 at 11:05 PMBBH-0.23%BIB-1.17%
